Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2024-06-04 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated June 4, 2024, informing stock exchanges about upcoming investor roadshows scheduled for June 5 and 6, 2024. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to disclosure of material events. The content is an announcement of planned investor meetings and explicitly states no unpublished price sensitive information will be shared. There are no financial statements, detailed financial data, or report attachments. The document is brief (1915 characters) and serves as a regulatory announcement rather than a financial report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings call held on May 24, 2024, discussing the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2024. It includes detailed management commentary on financial performance, operational updates, regulatory approvals, project timelines, and Q&A with analysts. The presence of a full transcript of the call, including management remarks and Q&A, clearly identifies this as a Call Transcript (CT). The document length (15,000 characters) and content confirm it is not a brief announcement or summary but a full transcript. Therefore, the appropriate classification is Call Transcript (CT).
2024-05-29 English
Copy of Newspaper Publication
Annual Report Classification · 95% confidence The document is a communication addressed to stock exchanges (NSE and BSE) regarding the publication of audited annual standalone and consolidated financial results for the quarter and financial year ended March 31, 2024. It references Regulation 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, which mandates disclosure of financial results. The document includes detailed financial data such as profit/loss figures and other financial metrics for the fiscal year ending March 31, 2024. The length of the document (15,000 characters) and the presence of substantive financial data indicate this is not merely an announcement or a certification but the actual financial results report. The content corresponds to a comprehensive annual financial report covering the full fiscal year, which aligns with the definition of an Annual Report (10-K equivalent in India). Therefore, the document should be classified as an Annual Report (10-K). FY 2024
2024-05-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated May 24, 2024, informing about the availability of the audio recording of an earnings call discussing the audited financial results for the quarter and financial year ended March 31, 2024. It references previous announcements and provides a link to the audio recording but does not contain the transcript or detailed financial data itself. The document length is only 1899 characters, which is quite short and consistent with an announcement rather than a full report or transcript. According to the rules, announcements about the availability of earnings call recordings should be classified as Regulatory Filings (RNS) because they do not contain the full transcript or substantive financial data. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2024-05-24 English
Appointment
Regulatory Filings
2024-05-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is titled 'Investors Presentation Q4-F.Y. 2023-24 – Orchid Pharma Limited' and is dated May 23, 2024. It references financial performance for the quarter ended March 31, 2024, and includes detailed financial highlights, charts, and analysis. The text explicitly states it is an 'Investor Presentation' and includes comprehensive financial data and performance metrics. There is no indication that this is a full annual report, audit report, or earnings release announcement. The document is not a brief announcement or a certification but a detailed presentation intended for investors. Therefore, the most appropriate classification is 'Investor Presentation' (IP). The document length (5444 characters) supports that it is a substantive presentation rather than a short announcement.
2024-05-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.